Suzanne T. Ildstad M.D.
Net Worth

Last updated:

What is Suzanne T. Ildstad M.D. net worth?

The estimated net worth of Dr. Suzanne T. Ildstad M.D. is at least $4,135,844 as of 14 Jun 2023. He has earned $2,677,634 from insider trading and has received compensation worth at least $1,458,210 in Talaris Therapeutics, Inc..

What is the salary of Suzanne T. Ildstad M.D.?

Dr. Suzanne T. Ildstad M.D. salary is $486,070 per year as Founder, Chief Scientific Officer & Director in Talaris Therapeutics, Inc..

How old is Suzanne T. Ildstad M.D.?

Dr. Suzanne T. Ildstad M.D. is 72 years old, born in 1953.

What stocks does Suzanne T. Ildstad M.D. currently own?

As insider, Dr. Suzanne T. Ildstad M.D. owns shares in one company:

Company Title Shares Price per share Total value
Talaris Therapeutics, Inc. (TALS) Founder, Chief Scientific Officer & Director 3,771,392 $0 $0

What does Talaris Therapeutics, Inc. do?

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.

TALS logo
TALS
Talaris Therapeutics, Inc.

Suzanne T. Ildstad M.D. insider trading

Talaris Therapeutics, Inc.

Dr. Suzanne T. Ildstad M.D. has made 22 insider trades between 2022-2023, according to the Form 4 filled with the SEC. Most recently he sold 12,942 units of TALS stock worth $32,239 on 14 Jun 2023.

The largest trade he's ever made was exercising 525,000 units of TALS stock on 22 Aug 2022. As of 14 Jun 2023 he still owns at least 3,771,392 units of TALS stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 12,942 $2.49 $32,239
Sale
Common Stock 14,208 $2.56 $36,344
Sale
Common Stock 16,870 $2.59 $43,727
Sale
Common Stock 25,419 $2.46 $62,632
Sale
Common Stock 40,642 $2.48 $100,792
Sale
Common Stock 75,001 $2.39 $179,102
Sale
Common Stock 25,549 $2.53 $64,588
Sale
Common Stock 7,841 $2.52 $19,751
Sale
Common Stock 15,818 $2.51 $39,624
Sale
Common Stock 15,713 $2.56 $40,178
Sale
Common Stock 15,004 $2.35 $35,229
Sale
Common Stock 46,990 $2.33 $109,299
Sale
Common Stock 21,753 $2.16 $47,052
Sale
Common Stock 49,211 $2.15 $105,804
Sale
Common Stock 99,771 $2.14 $213,510
Sale
Common Stock 20,872 $2.06 $43,080
Sale
Common Stock 6,806 $2.06 $13,993
Sale
Common Stock 29 $2.05 $59
Sale
Common Stock 3,500 $2.05 $7,186
Sale
Common Stock 3,612 $2.05 $7,405
Sale
Common Stock 2,939 $2.06 $6,040
Sale
Common Stock 525,000 $2.8 $1,470,000

Talaris Therapeutics key executives

Talaris Therapeutics, Inc. executives and other stock owners filed with the SEC: